Clinical Trials Logo

Lymphoma, Non-Hodgkin clinical trials

View clinical trials related to Lymphoma, Non-Hodgkin.

Filter by:

NCT ID: NCT02110563 Terminated - Multiple Myeloma Clinical Trials

Phase I, Multicenter, Dose Escalation Study of DCR-MYC in Patients With Solid Tumors, Multiple Myeloma, or Lymphoma

Start date: April 2014
Phase: Phase 1
Study type: Interventional

The purpose of this study is to assess the safety and tolerability of the investigational anticancer drug DCR-MYC. DCR-MYC is a novel synthetic double-stranded RNA in a stable lipid particle suspension that targets the oncogene MYC. MYC oncogene activation is important to the growth of many hematologic and solid tumor malignancies. In this study the Sponsor proposes to study DCR-MYC and its ability to inhibit MYC and thereby inhibit cancer cell growth.

NCT ID: NCT02109224 Terminated - Clinical trials for Chronic Lymphocytic Leukemia

Ibrutinib in Treating Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma in Patients With HIV Infection

Start date: September 2014
Phase: Phase 1
Study type: Interventional

This phase I trial studies the side effects and best dose of ibrutinib in treating B-cell non-Hodgkin lymphoma that has returned or does not respond to treatment in patients with human immunodeficiency virus (HIV) infection. Ibrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. It is not yet known whether it is safe for patients with HIV infection to receive ibrutinib while also taking anti-HIV drugs.

NCT ID: NCT02106091 Terminated - Clinical trials for Refractory B-Cell Non-Hodgkin Lymphoma

Safety Study to Assess AFM11 in Patients With Relapsed and/or Refractory CD19 Positive B-cell NHL

Start date: April 2014
Phase: Phase 1
Study type: Interventional

The purpose of this study is to determine whether AFM11 is safe and active in the treatment of relapsed and/or refractory Non-Hodgkin Lymphoma (NHL).

NCT ID: NCT02104427 Completed - Multiple Myeloma Clinical Trials

PD and Safety of TG-0054 Combined With G-CSF in Multiple Myeloma, Non-Hodgkin Lymphoma and Hodgkin Disease Patients

Start date: February 2015
Phase: Phase 2
Study type: Interventional

This is a phase II study to evaluate the efficacy and safety of TG-0054 combined with G-CSF in mobilizing hematopoietic stem cells in patients with multiple myeloma, non-Hodgkin lymphoma or Hodgkin disease.

NCT ID: NCT02099292 Completed - Clinical trials for Relapsed Non-Hodgkin-Lymphoma

Rituximab and DexaBEAM as Salvage Therapy for Relapsed Lymphoma

Mz-135
Start date: May 2001
Phase: Phase 2
Study type: Interventional

The investigator prospectively evaluated the combination of Rituximab and Dexa-BEAM (dexamethasone, carmustine, etoposide, cytarabine, melphalan) followed by high dose therapy in patients with relapsed/refractory aggressive and indolent lymphoma.

NCT ID: NCT02099266 Active, not recruiting - Clinical trials for Acute Myeloid Leukemia

Use of Hyperbaric Oxygen Therapy to Improve Umbilical Cord Blood Stem Cell Homing and Subsequent Engraftment

Start date: June 2013
Phase: N/A
Study type: Interventional

By doing this study, researchers hope to learn the following: - If providing hyperbaric oxygen (HBO) therapy prior to an umbilical cord blood (UBC) transplant will help to improve the homing process - The safety of HBO administration in the setting of the UBC transplant - The effects of HBO therapy on the engraftment process

NCT ID: NCT02098109 Completed - Multiple Myeloma Clinical Trials

Non-inferiority Study of XM02 Filgrastim (Granix) and Filgrastim (Neupogen) in Combination With Plerixafor for Autologous Stem Cell Mobilization in Patients With Multiple Myeloma or Non-Hodgkin Lymphoma

Start date: August 20, 2014
Phase: Phase 2
Study type: Interventional

This study will compare the results of stem cell mobilization using drugs called filgrastim (Neupogen) and plerixafor with the results of stem cell mobilization using drugs called XM02 filgrastim (Granix) and plerixafor.

NCT ID: NCT02095574 Withdrawn - Clinical trials for Relapsed/Refractory Non-Hodgkin's Lymphoma

A Pharmacokinetic Study to Access How the Body Absorbs and Removes ABT-199 in Adults With Non-Hodgkin's Lymphoma

Start date: September 2014
Phase: Phase 1
Study type: Interventional

A pharmacokinetic study to access how the body absorbs and removes ABT-199 in adults with Non-Hodgkin's Lymphoma.

NCT ID: NCT02087657 Active, not recruiting - Multiple Myeloma Clinical Trials

Pilot Study Exploring the Use of Hyperbaric Oxygen in Autologous Peripheral Blood Stem Cell Transplantation

Auto-HBO
Start date: March 2014
Phase: N/A
Study type: Interventional

By doing this study, researchers hope to learn the following: - The safety of hyperbaric oxygen administration in the setting of the autologous transplant - The effects of hyperbaric oxygen administration on neutrophil count recovery and engraftment

NCT ID: NCT02086175 Completed - Clinical trials for Relapsed/Refractory Indolent B Cell Non-Hodgkin Lymphomas

A Phase 2 Clinical Trial of Rituxan and B-Glucan PGG in Relapsed Indolent Non-Hodgkin Lymphoma

Start date: December 2014
Phase: Phase 2
Study type: Interventional

This research study is evaluating a drug combination called Imprime PGG and Rituximab as a possible treatment for relapsed/refractory indolent B cell non-Hodgkin lymphomas (NHL).